Long-term satisfaction and tolerability with low-dose flutamide: a 20-year surveillance study on 120 hyperandrogenic women

References

• March WA, Moore VM, Willson KJ, et al. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010;25:544–51
   PubMed Web of Science ®Google Scholar
• Hunt N, McHale S. The psychological impact of alopecia. BMJ 2005;331:951–3
   PubMed Web of Science ®Google Scholar
• Archer JS, Chang RJ. Hirsutism and acne in polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2004;18:737–54
   PubMed Web of Science ®Google Scholar
• van Zuuren EJ, Fedorowicz Z, American Medical Association. Interventions for hirsutism. JAMA 2015;314:1863–4
   PubMed Web of Science ®Google Scholar
• Karrer-Voegeli S, Rey F, Reymond MJ, et al. Androgen dependence of hirsutism, acne, and alopecia in women: retrospective analysis of 228 patients investigated for hyperandrogenism. Medicine (Baltimore) 2009;88:32–45
   PubMed Web of Science ®Google Scholar
• Mazza A, Fruci B, Guzzi P, et al. In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone. Nutr Metab Cardiovasc Dis 2014;24:132–9
   PubMed Web of Science ®Google Scholar
• Townsend K. a, Marlowe KF. Relative safety and efficacy of finasteride for treatment of hirsutism. Ann Pharmacother 2004;38:1070–3
   PubMed Web of Science ®Google Scholar
• Castelo-Branco C, Cancelo MJ. Comprehensive clinical management of hirsutism. Gynecol Endocrinol 2010;26:484–93
   PubMed Web of Science ®Google Scholar
• Moreno-Arias GA, Castelo-Branco C, Ferrando J. Side-effects after IPL photodepilation. Dermatol Surg 2002;28:1131–4
   PubMed Web of Science ®Google Scholar
• Shet MS, McPhaul M, Fisher CW, et al. Metabolism of the antiandrogenic drug (flutamide) by human CYP1A2. Drug Metab Dispos 1997;25:1298–303
   PubMed Web of Science ®Google Scholar
• Simard J, Luthy I, Guay J, et al. Characteristics of interaction of the antiandrogen flutamide with the androgen receptor in various target tissues. Mol Cell Endocrinol 1986;44:261–70
   PubMed Web of Science ®Google Scholar
• Goodman NF, Cobin RH, Futterweit W, et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and androgen excess and PCOS Society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome – PART 1. Endocr Pract 2015;21:1291–300
   PubMed Web of Science ®Google Scholar
• Bruni V, Peruzzi E, Dei M, et al. Hepatotoxicity with low- and ultralow-dose flutamide: a surveillance study on 203 hyperandrogenic young females. Fertil Steril 2012;98:1047–52
   PubMed Web of Science ®Google Scholar
• Castelo-Branco C, Moyano D, Gómez O, Balasch J. Long-term safety and tolerability of flutamide for the treatment of hirsutism. Fertil Steril 2009;91:1183–8
   PubMed Web of Science ®Google Scholar
• Ferriman D, Gallwey JD, The Endocrine Society. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440–7
   PubMed Web of Science ®Google Scholar
• Balasch J, Fábregues F, Peñarrubia J, et al. Pretreatment with transdermal testosterone may improve ovarian response to gonadotrophins in poor-responder IVF patients with normal basal concentrations of FSH. Hum Reprod 2006;21:1884–93
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Nukui A, Suzuki K, et al. Clinical efficacy of primary combined androgen blockade for Japanese men with clinically localized prostate cancer unsuitable for local definitive treatment: a single institution experience. Int J Clin Oncol 2011;16:630–6
   PubMed Web of Science ®Google Scholar
• Bolla M, de Reijke TM, van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009;360:2516–27
   PubMed Web of Science ®Google Scholar
• Bañez LL, Blake GW, McLeod DG, et al. Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up. BJU Int 2009;104:310–14
   PubMed Web of Science ®Google Scholar
• Paradisi R, Fabbri R, Porcu E, et al. Retrospective, observational study on the effects and tolerability of flutamide in a large population of patients with acne and seborrhea over a 15-year period. Gynecol Endocrinol 2011;27:823–9
   PubMed Web of Science ®Google Scholar
• Paradisi R, Venturoli S. Retrospective observational study on the effects and tolerability of flutamide in a large population of patients with various kinds of hirsutism over a 15-year period. Eur J Endocrinol 2010;163:139–47
   PubMed Web of Science ®Google Scholar
• Ibáñez L, Diaz M, Sebastiani G, et al. Treatment of androgen excess in adolescent girls: ethinylestradiol-cyproteroneacetate versus low-dose pioglitazone-flutamide-metformin. J Clin Endocrinol Metab 2011;96:3361–6
   PubMed Web of Science ®Google Scholar
• Paradisi R, Porcu E, Fabbri R, et al. Prospective cohort study on the effects and tolerability of flutamide in patients with female pattern hair loss. Ann Pharmacother 2011;45:469–75
   PubMed Web of Science ®Google Scholar
• Domecq JP, Prutsky G, Mullan RJ, et al. Adverse effects of the common treatments for polycystic ovary syndrome: a systematic review and meta-analysis. J Clin Endocrinol Metab 2013;98:4646–54
   PubMed Web of Science ®Google Scholar
• Calaf J, López E, Millet A, et al. Long-term efficacy and tolerability of flutamide combined with oral contraception in moderate to severe hirsutism: a 12-month, double-blind, parallel clinical trial. J Clin Endocrinol Metab 2007;92:3446–52
   PubMed Web of Science ®Google Scholar
• Castelo-Branco C, del Pino M. Hepatotoxicity during low-dose flutamide treatment for hirsutism. Gynecol Endocrinol 2009;25:419–22
   PubMed Web of Science ®Google Scholar
• Thole Z, Manso G, Salgueiro E, et al. Hepatotoxicity induced by antiandrogens: a review of the literature. Urol Int 2004;73:289–95
   PubMed Web of Science ®Google Scholar
• Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008;358:1250–61
   PubMed Web of Science ®Google Scholar